30% Less Than TOPCon, Risen Energy reduce Silver Consumption of HJT Hyper-ion Module to <7mg/W
NINGBO, China, Feb. 3, 2024 /PRNewswire/ -- Recently, Risen Energy announced that it has successfully reduced silver consumption in its Heterojunction (HJT) Hyper-ion solar modules to less than 7mg per watt, not only significantly better than both...
CGTN: Spending time with the people: Xi Jinping's Chinese New Year tradition
BEIJING, Feb. 3, 2024 /PRNewswire/ -- In a village greenhouse in north China's Tianjin Municipality, vegetables and fruits are waiting to be picked and transported. Some have been packaged for delivery to be served on people's dining tables. Diliubu...
KEENON Robotics' DINERBOT T9 Pro Receives Esteemed 2023 GOOD DESIGN® Award by The Chicago Athenaeum: Museum of Architecture and Design
CHICAGO, Feb. 3, 2024 /PRNewswire/ -- KEENON Robotics is delighted to announce the recognition of its DINERBOT T9 Pro, an autonomous delivery robot, honored with the esteemed 2023 GOOD DESIGN® Award by The Chicago Athenaeum: Museum of Architecture...
Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke....
Lumicore Champions Micro-OLED Display Technology for Better Immersive Experiences
SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- Lumicore, the leading manufacturer of high-resolution, low-power consumption Micro-OLED displays, has recently closed Series A funding of $100 million and has also received recognition from prominent headset...
Universal Robots reports strong end to 2023
ODENSE, Denmark, Feb. 2, 2024 /PRNewswire/ -- Universal Robots, the Danish collaborative robot (cobot) company, has reported Q4 revenue of USD 103 million, up 21% on Q4 2022. The quarter was the company's largest revenue quarter to date. 2023 annual...
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor Inmagene...
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day...